Loading…

Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study

Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The...

Full description

Saved in:
Bibliographic Details
Published in:BMC Infectious Diseases 2018, Vol.18 (1)
Main Authors: Oh, Dong Hyun, Kim, Jung Ju, Kim, Jinnam, Seong, Hye, Lee, Se Ju, Kim, Yong Chan, Kim, Eun Jin, Jung, In Young, Jeong, Woo Yong, Jeong, Su Jin, Ku, Nam Su, Han, Sang Hoon, Choi, Jun Yong, Song, Young Goo, Kim, June Myung
Format: Report
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 1
container_start_page
container_title BMC Infectious Diseases
container_volume 18
creator Oh, Dong Hyun
Kim, Jung Ju
Kim, Jinnam
Seong, Hye
Lee, Se Ju
Kim, Yong Chan
Kim, Eun Jin
Jung, In Young
Jeong, Woo Yong
Jeong, Su Jin
Ku, Nam Su
Han, Sang Hoon
Choi, Jun Yong
Song, Young Goo
Kim, June Myung
description Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.
doi_str_mv 10.1186/s12879-018-2978-z
format report
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_incontextgauss_IOV_A546399434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A546399434</galeid><sourcerecordid>A546399434</sourcerecordid><originalsourceid>FETCH-gale_incontextgauss_IOV_A5463994343</originalsourceid><addsrcrecordid>eNqVjb1OxDAQhC0EEsfPA9BtSxGIk3BJ6NAJBBUFiPa056wvRj478m6A8GQ8HhxQ0FLNjDTzjVInOj_Tupmfsy6aus1y3WRFWzfZ-46a6arWWVGW1e4fv68OmJ_zXNdN0c7UxyJuBkyOY4BoQXoCstYZNNM2B7TGee8CYOhg7ScTBxrEdcSADB1ZF5y4F9ouEw4T2JhgQHEUhOHVSQ8bkt79UDIe2Wz3K0_wIDj0k48mGjN-4cZEX7JCI5Ro4_ASEBJJijyQ-f4wsY9JgGXspiO1Z9EzHf_qoTq9uX5c3GZr9LR0wcQg9CZrHJmXd_dPy6uLal62bVVW5X-6nzv1cvM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype></control><display><type>report</type><title>Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Oh, Dong Hyun ; Kim, Jung Ju ; Kim, Jinnam ; Seong, Hye ; Lee, Se Ju ; Kim, Yong Chan ; Kim, Eun Jin ; Jung, In Young ; Jeong, Woo Yong ; Jeong, Su Jin ; Ku, Nam Su ; Han, Sang Hoon ; Choi, Jun Yong ; Song, Young Goo ; Kim, June Myung</creator><creatorcontrib>Oh, Dong Hyun ; Kim, Jung Ju ; Kim, Jinnam ; Seong, Hye ; Lee, Se Ju ; Kim, Yong Chan ; Kim, Eun Jin ; Jung, In Young ; Jeong, Woo Yong ; Jeong, Su Jin ; Ku, Nam Su ; Han, Sang Hoon ; Choi, Jun Yong ; Song, Young Goo ; Kim, June Myung</creatorcontrib><description>Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p &lt; 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p &lt; 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.</description><identifier>ISSN: 1471-2334</identifier><identifier>EISSN: 1471-2334</identifier><identifier>DOI: 10.1186/s12879-018-2978-z</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Bacteremia ; Care and treatment ; Chemical properties ; Dosage and administration ; Glycoproteins ; Nafcillin ; Staphylococcus aureus</subject><ispartof>BMC Infectious Diseases, 2018, Vol.18 (1)</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,780,4476,27902</link.rule.ids></links><search><creatorcontrib>Oh, Dong Hyun</creatorcontrib><creatorcontrib>Kim, Jung Ju</creatorcontrib><creatorcontrib>Kim, Jinnam</creatorcontrib><creatorcontrib>Seong, Hye</creatorcontrib><creatorcontrib>Lee, Se Ju</creatorcontrib><creatorcontrib>Kim, Yong Chan</creatorcontrib><creatorcontrib>Kim, Eun Jin</creatorcontrib><creatorcontrib>Jung, In Young</creatorcontrib><creatorcontrib>Jeong, Woo Yong</creatorcontrib><creatorcontrib>Jeong, Su Jin</creatorcontrib><creatorcontrib>Ku, Nam Su</creatorcontrib><creatorcontrib>Han, Sang Hoon</creatorcontrib><creatorcontrib>Choi, Jun Yong</creatorcontrib><creatorcontrib>Song, Young Goo</creatorcontrib><creatorcontrib>Kim, June Myung</creatorcontrib><title>Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study</title><title>BMC Infectious Diseases</title><description>Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p &lt; 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p &lt; 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.</description><subject>Bacteremia</subject><subject>Care and treatment</subject><subject>Chemical properties</subject><subject>Dosage and administration</subject><subject>Glycoproteins</subject><subject>Nafcillin</subject><subject>Staphylococcus aureus</subject><issn>1471-2334</issn><issn>1471-2334</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2018</creationdate><recordtype>report</recordtype><recordid>eNqVjb1OxDAQhC0EEsfPA9BtSxGIk3BJ6NAJBBUFiPa056wvRj478m6A8GQ8HhxQ0FLNjDTzjVInOj_Tupmfsy6aus1y3WRFWzfZ-46a6arWWVGW1e4fv68OmJ_zXNdN0c7UxyJuBkyOY4BoQXoCstYZNNM2B7TGee8CYOhg7ScTBxrEdcSADB1ZF5y4F9ouEw4T2JhgQHEUhOHVSQ8bkt79UDIe2Wz3K0_wIDj0k48mGjN-4cZEX7JCI5Ro4_ASEBJJijyQ-f4wsY9JgGXspiO1Z9EzHf_qoTq9uX5c3GZr9LR0wcQg9CZrHJmXd_dPy6uLal62bVVW5X-6nzv1cvM</recordid><startdate>20180130</startdate><enddate>20180130</enddate><creator>Oh, Dong Hyun</creator><creator>Kim, Jung Ju</creator><creator>Kim, Jinnam</creator><creator>Seong, Hye</creator><creator>Lee, Se Ju</creator><creator>Kim, Yong Chan</creator><creator>Kim, Eun Jin</creator><creator>Jung, In Young</creator><creator>Jeong, Woo Yong</creator><creator>Jeong, Su Jin</creator><creator>Ku, Nam Su</creator><creator>Han, Sang Hoon</creator><creator>Choi, Jun Yong</creator><creator>Song, Young Goo</creator><creator>Kim, June Myung</creator><general>BioMed Central Ltd</general><scope>IOV</scope></search><sort><creationdate>20180130</creationdate><title>Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study</title><author>Oh, Dong Hyun ; Kim, Jung Ju ; Kim, Jinnam ; Seong, Hye ; Lee, Se Ju ; Kim, Yong Chan ; Kim, Eun Jin ; Jung, In Young ; Jeong, Woo Yong ; Jeong, Su Jin ; Ku, Nam Su ; Han, Sang Hoon ; Choi, Jun Yong ; Song, Young Goo ; Kim, June Myung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_incontextgauss_IOV_A5463994343</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bacteremia</topic><topic>Care and treatment</topic><topic>Chemical properties</topic><topic>Dosage and administration</topic><topic>Glycoproteins</topic><topic>Nafcillin</topic><topic>Staphylococcus aureus</topic><toplevel>online_resources</toplevel><creatorcontrib>Oh, Dong Hyun</creatorcontrib><creatorcontrib>Kim, Jung Ju</creatorcontrib><creatorcontrib>Kim, Jinnam</creatorcontrib><creatorcontrib>Seong, Hye</creatorcontrib><creatorcontrib>Lee, Se Ju</creatorcontrib><creatorcontrib>Kim, Yong Chan</creatorcontrib><creatorcontrib>Kim, Eun Jin</creatorcontrib><creatorcontrib>Jung, In Young</creatorcontrib><creatorcontrib>Jeong, Woo Yong</creatorcontrib><creatorcontrib>Jeong, Su Jin</creatorcontrib><creatorcontrib>Ku, Nam Su</creatorcontrib><creatorcontrib>Han, Sang Hoon</creatorcontrib><creatorcontrib>Choi, Jun Yong</creatorcontrib><creatorcontrib>Song, Young Goo</creatorcontrib><creatorcontrib>Kim, June Myung</creatorcontrib><collection>Opposing Viewpoints Resource Center</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oh, Dong Hyun</au><au>Kim, Jung Ju</au><au>Kim, Jinnam</au><au>Seong, Hye</au><au>Lee, Se Ju</au><au>Kim, Yong Chan</au><au>Kim, Eun Jin</au><au>Jung, In Young</au><au>Jeong, Woo Yong</au><au>Jeong, Su Jin</au><au>Ku, Nam Su</au><au>Han, Sang Hoon</au><au>Choi, Jun Yong</au><au>Song, Young Goo</au><au>Kim, June Myung</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study</atitle><jtitle>BMC Infectious Diseases</jtitle><date>2018-01-30</date><risdate>2018</risdate><volume>18</volume><issue>1</issue><issn>1471-2334</issn><eissn>1471-2334</eissn><abstract>Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p &lt; 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p &lt; 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.</abstract><pub>BioMed Central Ltd</pub><doi>10.1186/s12879-018-2978-z</doi></addata></record>
fulltext fulltext
identifier ISSN: 1471-2334
ispartof BMC Infectious Diseases, 2018, Vol.18 (1)
issn 1471-2334
1471-2334
language eng
recordid cdi_gale_incontextgauss_IOV_A546399434
source Publicly Available Content Database; PubMed Central
subjects Bacteremia
Care and treatment
Chemical properties
Dosage and administration
Glycoproteins
Nafcillin
Staphylococcus aureus
title Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T18%3A18%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Comparison%20of%20the%20efficacy%20of%20nafcillin%20and%20glycopeptides%20as%20definitive%20therapy%20for%20patients%20with%20methicillin-susceptible%20Staphylococcus%20aureus%20bacteremia:%20a%20retrospective%20cohort%20study&rft.jtitle=BMC%20Infectious%20Diseases&rft.au=Oh,%20Dong%20Hyun&rft.date=2018-01-30&rft.volume=18&rft.issue=1&rft.issn=1471-2334&rft.eissn=1471-2334&rft_id=info:doi/10.1186/s12879-018-2978-z&rft_dat=%3Cgale%3EA546399434%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-gale_incontextgauss_IOV_A5463994343%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A546399434&rfr_iscdi=true